US2022370552A1PendingUtilityA1
Compositions and methods for enhancing neuro-repair
Est. expiryDec 13, 2037(~11.4 yrs left)· nominal 20-yr term from priority
Inventors:Gregory J. Bix
A61P 25/00C07K 14/4725A61P 25/28A61K 38/1709A61K 9/0019
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods for enhancing recovery after an ischemic injury, including cerebral ischemia and stroke, by administration of therapeutic amounts of Domain V protein.
Claims
exact text as granted — not AI-modified1 . A method of enhancing neurogenic neurorepair in a subject in need comprising:
administering Perlecan Domain V (DV) or DV fragment to the subject, wherein administration of DV or DV fragment increases the number of new post-ischemic event mature neurons in an area of the brain of the subject damaged by the ischemic event.
2 . The method of claim 1 , wherein the subject has had a traumatic brain injury or stroke.
3 . The method of claim 2 , wherein DV or DV fragment is first administered to the subject more than 24 hours after the traumatic brain injury or stroke to increase neurogenesis.
4 . The method of claim 1 , wherein the DV fragment is LG3.
5 . The method of claim 1 , wherein the administering occurs daily for a period of 1 day to two weeks.
6 . The method of claim 1 , wherein the administering step includes administering about 0.5 mg/kg to about 20 mg/kg of the DV.
7 . The method of claim 1 , wherein neural precursor cells and/or peri-infarct neurite density is increased.
8 . The method of claim 1 , wherein administering the DV includes administering the DV intravenously or administering the DV intraperitoneally.
9 . The method of claim 1 , wherein the administering increases neurogenesis, increases neuron survival, improves functional recovery, improves motor function, increases outgrowth of new neurons, restores excitatory synaptic transmission, reverses ischemic induced changes to excitatory post synaptic currents, increases neurosphere expansion, and/or increases neuroblast migration compared to a control subject that does not receive DV.
10 . The method of claim 1 , wherein the subject is a mammal.
11 . The method of claim 10 , wherein the subject is a mouse or a human.Join the waitlist — get patent alerts
Track US2022370552A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.